A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS

Exclusion Criteria

• •Any of the following within the specified window prior to the first dose of study drug
• •Prior hematopoietic stem cell or bone marrow transplantation
• •Prior radiotherapy to \> 25% of bone marrow
• •Brain metastases that require immediate treatment or are clinically or radiologically unstable (i.e., have been stable for \< 1 month). If receiving steroids, subjects must be receiving a stable to decreasing corticosteroid dose during at least 1 week before enrollment.
• •Leptomeningeal disease that requires or is anticipated to require immediate treatment.
• •Presence of life-threatening metastatic visceral disease or symptomatic pulmonary lymphangitic spread
• •Other known active cancer(s) likely to require treatment in the next year that would impact the assessment of any study endpoints
• •\[Female subjects\]: Pregnant or breast-feeding
• •Unexplained symptomatic endometrial disorders (including, but not limited to endometrial hyperplasia, dysfunctional uterine bleeding, or cysts)
• •Impairment of gastrointestinal (GI) absorption for oral medications
• •Nausea, vomiting, or diarrhea \> Grade 1
• •Myocardial infarction, symptomatic congestive heart failure (NYHA \> Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months
• •QTc interval \> 480 msec (based on the mean value of the triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or history of Torsade de Pointes
• •Concurrent use of food or drugs known to be moderate or strong CYP3A or CYP2C9 inducers and moderate or strong CYP3A4 or CYP2C9 inhibitors.
• •Positive serum virological tests (HBsAg, HCV-AB, HIV-AB, TP-AB) at screening stage will be excluded.
• •Any clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Medical Monitor would pose a risk to subject safety or interfere with the study evaluations, procedures, or completion